2016 SRS Acquiom Life Science M&A Earnout Achievement UpdateDecember 1, 2016
The 2016 SRS Acquiom Life Sciences M&A Earnout Achievement Update presents almost a decade’s worth of experience managing over 100 deals with more than $27 billion in potential milestone payments. By now, over 200 separate milestones have become due, 10 times that described in our seminal 2012 Life Sciences M&A Study. Key data is presented on the percentages of milestones paid, including by sub-industry and development phase, as well as on earnout disputes, renegotiations, and best practices for managing these deals post-closing.
About the Author
Head of Life Sciences
Don advises life science clients on M&A deal negotiations and post-closing milestones and earnouts. An accomplished business executive and attorney, Don brings over 20 years of expertise in the life sciences sector. Don helped grow two venture-backed start-up companies through initial public offerings. He has been responsible for many strategic transactions involving licensing, partnering and M&A, as well as financings with leading venture capital and private equity firms. He was formerly SVP, Corporate Development and General Counsel for Replidyne, an antibiotic drug development company, and VP, Legal Affairs and Business Development for Caliper Life Sciences, a microfluidics company. He began his career as a business attorney with Cooley LLP. Don holds a JD from the University of Southern California and a BA in molecular, cellular and developmental biology from the University of Colorado.